SEC Form SC 13G/A filed by Anika Therapeutics Inc. (Amendment)

$ANIK
Medical/Dental Instruments
Health Care
Get the next $ANIK alert in real time by email
SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 11 )*

            

Anika Therapeutics Inc


(Name of Issuer)

Common Stock


(Title of Class of Securities)

035255108


(CUSIP Number)

December 29, 2023


(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


CUSIP No. 035255108

1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Dimensional Fund Advisors LP
30-0447847
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) [ ]
(b) [X]
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware Limited Partnership

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER 803,968 ** see Note 1 **
6. SHARED VOTING POWER 0
7. SOLE DISPOSITIVE POWER 821,452 ** see Note 1 **
8. SHARED DISPOSITIVE POWER 0
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

821,452 ** see Note 1 **
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

[ ]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.6%
12. TYPE OF REPORTING PERSON

IA




















Item 1.
(a) Name of Issuer
Anika Therapeutics Inc
(b) Address of Issuer's Principal Executive Offices
32 Wiggins Avenue, Bedford, MA 01730
Item 2.
(a) Name of Person Filing
Dimensional Fund Advisors LP
(b) Address of Principal Business Office or, if None, Residence
6300 Bee Cave Road, Building One, Austin, TX 78746
(c) Citizenship
Delaware Limited Partnership
(d) Title of Class of Securities
Common Stock
(e) CUSIP Number
035255108
Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
(a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
(b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
(d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
(h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
Item 4. Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount Beneficially Owned:
821,452 ** see Note 1 **
(b) Percent of Class:
5.6%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote 803,968 ** see Note 1 **
(ii) shared power to vote or to direct the vote 0
(iii) sole power to dispose or to direct the disposition of 821,452 ** see Note 1 **
(iv) shared power to dispose or to direct the disposition of 0
** Note 1 ** Dimensional Fund Advisors LP, an investment adviser registered under Section 203 of the Investment Advisors Act of 1940, furnishes investment advice to four investment companies registered under the Investment Company Act of 1940, and serves as investment manager or sub-adviser to certain other commingled funds, group trusts and separate accounts (such investment companies, trusts and accounts, collectively referred to as the "Funds"). In certain cases, subsidiaries of Dimensional Fund Advisors LP may act as an adviser or sub-adviser to certain Funds. In its role as investment advisor, sub-adviser and/or manager, Dimensional Fund Advisors LP or its subsidiaries (collectively, "Dimensional") may possess voting and/or investment power over the securities of the Issuer that are owned by the Funds, and may be deemed to be the beneficial owner of the shares of the Issuer held by the Funds. However, all securities reported in this schedule are owned by the Funds. Dimensional disclaims beneficial ownership of such securities. In addition, the filing of this Schedule 13G shall not be construed as an admission that the reporting person or any of its affiliates is the beneficial owner of any securities covered by this Schedule 13G for any other purposes than Section 13(d) of the Securities Exchange Act of 1934.
Item 5. Ownership of Five Percent or Less of Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
The Funds described in Note 1 above have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the securities held in their respective accounts. To the knowledge of Dimensional, the interest of any one such Fund does not exceed 5% of the class of securities. Dimensional Fund Advisors LP disclaims beneficial ownership of all such securities.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
Not Applicable
Item 8. Identification and Classification of Members of the Group.

Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
Item 9. Notice of Dissolution of Group.

Not Applicable
Item 10. Certification.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dimensional Fund Advisors LP
By: Dimensional Holdings Inc., General Partner
By: /s/ Selwyn Notelovitz
Date: February 14, 2024
Name: Selwyn Notelovitz
Title: Global Chief Compliance Officer

Get the next $ANIK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ANIK

DatePrice TargetRatingAnalyst
11/1/2024$37.00 → $25.00Outperform
Barrington Research
8/14/2023$24.00Mkt Perform → Outperform
Barrington Research
3/7/2023Outperform → Mkt Perform
Barrington Research
11/9/2022$31.00Mkt Perform → Outperform
Barrington Research
10/14/2022$26.00Equal-Weight
Stephens
3/9/2022Outperform → Mkt Perform
Barrington Research
3/9/2022Overweight → Equal-Weight
Stephens & Co.
3/9/2022$35.00Overweight → Equal-Weight
Stephens
More analyst ratings

$ANIK
Press Releases

Fastest customizable press release news feed in the world

See more
  • Anika Reports Fourth Quarter and Full Year 2024 Financial Results

    Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to generate significantly higher returns BEDFORD, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the Osteoarthritis ("OA") Pain Management and Regenerative Solutions space focused on early intervention orthoped

    $ANIK
    Medical/Dental Instruments
    Health Care
  • Anika Completes Divestiture of Parcus Medical

    BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the Osteoarthritis Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced the completion of the previously announced planned divestiture of its Parcus Medical business. Management Commentary"The sale of Parcus marks a critical step forward as we achieve the goals of our previously announced strategic review. We are better positioned than ever to fully focus on our core hyaluronic acid technology and advance our differentiated and growing Regenerative Solutions portfolio." said Cheryl R. Blanchard, Ph.D., President and Chief Exec

    $ANIK
    Medical/Dental Instruments
    Health Care
  • Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025

    BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2024 financial results after the close of the market on Wednesday, March 12, 2025 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89368. A live audio webcast and accompanying presentation materials will be available in the Investor

    $ANIK
    Medical/Dental Instruments
    Health Care

$ANIK
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ANIK
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANIK
SEC Filings

See more

$ANIK
Leadership Updates

Live Leadership Updates

See more
  • Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    $A
    $ANIK
    $AVNT
    $MASI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care
  • Anika Enters into Cooperation Agreement with Caligan Partners

    Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP ("Caligan"). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed to the Company's Board of Directors, effective immediately. Messrs. Capper and Jellison have nearly 50 years of combined experience building value and driving transformative growth at MedTech compa

    $ANIK
    Medical/Dental Instruments
    Health Care
  • Anika Announces CFO Transition

    BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice President, Chief Financial Officer ("CFO") and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition. "We are pleased to welcome Steve to Anika as we focus on accelerating our pivot to profitability," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "Steve

    $ANIK
    $VSEC
    Medical/Dental Instruments
    Health Care
    Military/Government/Technical
    Consumer Discretionary

$ANIK
Financials

Live finance-specific insights

See more
  • Anika Reports Fourth Quarter and Full Year 2024 Financial Results

    Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to generate significantly higher returns BEDFORD, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the Osteoarthritis ("OA") Pain Management and Regenerative Solutions space focused on early intervention orthoped

    $ANIK
    Medical/Dental Instruments
    Health Care
  • Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025

    BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2024 financial results after the close of the market on Wednesday, March 12, 2025 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89368. A live audio webcast and accompanying presentation materials will be available in the Investor

    $ANIK
    Medical/Dental Instruments
    Health Care
  • Anika Reports Third Quarter 2024 Financial Results

    Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds Strategy to focus on market leading OA Pain Management and high-growth Regenerative Solutions Company to categorize revenue into OEM Channel and Commercial Channel; Commercial Channel remains on track to achieve ~17% CAGR since 2021 with recent performance fueled by the IntegrityTM Implant System, which grew 40%+ sequentially in the third quarter with more than 500 surgeries since launch First module of Hyalofast® PMA filed in October; important hurdle addressed regarding Cingal® NDA filin

    $ANIK
    Medical/Dental Instruments
    Health Care

$ANIK
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more